spacer
home > pmps > winter 2018 > hailing technology
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Hailing Technology

Can you explain the different types of inhalation drug delivery devices?

The majority of inhalation drug delivery devices fall into three different categories: nebulisers, pressurised metered dose inhalers (pMDI), and dry powder inhalers (DPIs). Other unique delivery systems are available that do not fall into these, but the vast majority can be classified as one of these three. Also, variations or subgroupings exist within each of these device categories. For example, substantial advancements have been made in the area of nebulisers over the past 10 years or so. Prior to that timeframe, the majority of nebulisers were compressed air jet nebulisers. During this time, significant progress has been made in the area of vibrating mesh and ultrasonic nebulisers. Similarly, within each of pMDI and DPIs are subsets. Often, these arise out of novel developments or the need for unique capabilities to address a problem statement.

What are their respective benefits and downsides?


Each device has different benefits and limitations. These include attributes like ease of use, portability, duration of time to deliver the dose, and dose range supported. For example, many of the advancements in current nebuliser technologies have been to make them more portable. Previous generations required an electrical power source to operate the compressor, and this limited the patient’s ability to utilise their therapies when they were not at home. Another limitation that each device has is the range of dose(s) that can be delivered. Often, pMDIs are considered to have a lower dose range than DPIs, which are both typically lower than nebulisers. However, DPIs and pMDIs typically deliver the medication in a single bolus dose, while nebulisers can require 5-15 minutes to deliver a dose.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Philip Kuehl completed his PhD at the University of Arizona, College of Pharmacy in Pharmaceutical Sciences, US, in 2007. Afterwards, he joined the applied life sciences programme at Lovelace Biomedical, where he has worked since 2007. Philip is currently a Research Scientist at LRRI and the Director of Scientific Core Laboratories. His research interests are in the area of inhalation formulation and its effects on deposition, pharmacokinetics, and pharmacodynamics. Philip also serves as on the editorial board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery and as an ad hoc reviewer for several inhalation and pharmaceutical science-based journals.
spacer
Dr Philip Kuehl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

Bio Europe Spring 2019

25-27 March 2019, Messe Wien Exhibition and Congress Center, Vienna

BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement